Compare Opendoor Technologies Inc (OPEN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Opendoor Technologies Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Opendoor Technologies Inc trades at $2.32 (market cap $2.22B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 57.5× Opendoor Technologies Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Opendoor Technologies Inc for 33 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| OPEN | VRTX | |
|---|---|---|
Market Cap | $2.22B | $127.55B |
Volume | 28,705,892 | 1,487,944 |
Sector | Real Estate | Health |
52-Week High | $9.37 | $557.96 |
52-Week Low | $2.27 | $407.37 |
Typical Hold Time | 33 Days | 120 Days |
Enterprise Value | $3.29B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Opendoor Technologies (OPEN) trades at $2.27 with no recent price movement, reflecting ongoing investor caution. The stock shows bearish technical signals with most moving averages and oscillators indicating selling pressure. Fundamentally, the company continues to struggle with profitability, posting a -46.74% net income margin and -$1.30B net loss in 2025 despite $4.37B revenue. Recent news highlights the company's mortgage expansion strategy and ongoing challenges in the housing market.
While analyst consensus suggests significant upside potential with a $4.92 price target, the company faces substantial execution risks amid persistent losses and high debt levels. The path to profitability remains uncertain, with revenue declining from $15.6B in 2022 to $4.4B in 2025. Investors should weigh the discounted valuation against ongoing operational challenges in the volatile housing sector.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
